Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024

Akriti Jain, MD, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.

She highlights her anticipation for several abstracts, particularly those focused on acute myeloid leukemia (AML). Jain is especially looking forward to the presentation of research on combining venetoclax (Venclexta) with the traditional 7+3 chemotherapy regimen.

Venetoclax has shown promise in AML treatment, particularly in combination with azacitadine, and its potential in conjunction with 7+3 could provide significant improvements in patient outcomes. This research is especially important as patients with AML still face challenging outcomes despite ongoing treatment efforts.

Transcription:

0:10 | We are all very excited for the 2024 ASH Meeting in San Diego, where I am going soon. So, I think that some of the exciting abstracts that we are looking forward to [seeing] are actually in acute myeloid leukemia. There are some in chronic myeloid leukemia and MPNS as well, but the most exciting abstract that I am looking forward to is 7 plus 3 plus venetoclax.

0:37 | So, for [patients with] acute leukemia, 7 plus 3 has been the standard since the 70s, and we are looking forward to adding more than a third. For example, a third medication to the 7 plus 3 backbone to see how that can help our patients. And we know venetoclax [which] works really well in combination with either azacitadine for AML, and we are excited to know how it would do in combination with 7 plus 3. So, there are a lot of exciting newer AML regimens for our patients that really need help with outcomes of our AML patients being poor, still given everything we are trying to do to improve them